Navigation Links
Scientists Can't Replicate Surprising Finding on Alzheimer's Treatment
Date:5/23/2013

THURSDAY, May 23 (HealthDay News) -- Although a study in 2012 suggested a cancer drug could reverse the thinking and memory problems associated with Alzheimer's disease, three groups of researchers now say they have been unable to duplicate those findings.

The teams said their research could have serious implications for patient safety since the drug involved in the study, bexarotene (Targretin), has serious side effects, such as major blood-lipid abnormalities, pancreatitis, headaches, fatigue, weight gain, depression, nausea, vomiting, constipation and rash.

"Anecdotally, we have all heard that physicians are treating their Alzheimer's patients with bexarotene, a cancer drug with severe side effects," said study co-author Robert Vassar, a professor of cell and molecular biology at Northwestern University Feinberg School of Medicine, in Chicago. "This practice should be ended immediately, given the failure of three independent research groups to replicate the plaque-lowering effects of bexarotene."

The U.S. Food and Drug Administration approved bexarotene in 1999 to treat refractory cutaneous T-cell lymphoma. Once approved, however, the drug also was available by prescription for "off-label" uses.

The 2012 study suggested that bexarotene was able to rapidly reverse the build-up of beta amyloid plaques in the brains of mice. The authors of the initial study concluded that treatment with the drug might reverse the cognitive and memory problems associated with the development of Alzheimer's.

Sangram Sisodia, a professor of neurosciences at the University of Chicago and a study co-author of the latest research, admitted being skeptical about the initial findings.

"We were surprised and excited -- even stunned -- when we first saw these results presented at a small conference," Sisodia said in a University of Chicago Medical Center news release. "The mechanism of action made some sense, but the assertion that they could reduce the areas of plaque by 50 percent within three days and by 75 percent in two weeks seemed too good to be true."

In attempting to duplicate the findings, the research teams found that they were indeed too good to be true.

"We all went back to our labs and tried to confirm these promising findings," Sisodia said. "We repeated the initial experiments -- a standard process in science. Combined results are really important in this field. None of us found anything like what they described in the 2012 paper."

Researchers at the University of Chicago, Northwestern University, Massachusetts General Hospital, Washington University in St Louis and the University of Tubingen in Germany reported in the May 24 issue of the journal Science that they did not find any reduction in beta amyloid plaques during or after treatment with bexarotene in three different strains of mice.

Bexarotene has never been tested on people as a treatment for Alzheimer's disease. Currently, there is no cure or effective treatment for the progressive condition, which affects an estimated 5.3 million Americans.

More information

The U.S. National Institutes of Health provides more information on Alzheimer's disease.

-- Mary Elizabeth Dallas

SOURCE: University of Chicago Medical Center, news release, May 23, 2013.


'/>"/>
Copyright©2012 ScoutNews,LLC.
All rights reserved  

Related medicine news :

1. Scientists solving the mystery of human consciousness
2. Scientists uncover multiple faces of deadly breast cancer
3. Scientists identify major source of cells defense against oxidative stress
4. Scientists tailor cell surface targeting system to hit organelle ZIP codes
5. Scientists rewrite rulebook on breast cancer in landmark global study
6. Warwick scientists uncover how checkpoint proteins bind chromosomes
7. NIH scientists link quickly spreading gene to Asian MRSA epidemic
8. Joslin scientists identify important mechanism that affects the aging process
9. Scripps Research scientists show how memory B cells stay in class to fight different infections
10. Scientists Map Melanomas Genome
11. A*STAR scientists discover switch to boost anti-viral response to fight infectious diseases
Post Your Comments:
*Name:
*Comment:
*Email:
Related Image:
Scientists Can't Replicate Surprising Finding on Alzheimer's Treatment
(Date:6/24/2016)... ... June 24, 2016 , ... The Pulmonary Hypertension Association (PHA) ... will receive two significant new grants to support its work to advance research ... anniversary by recognizing patients, medical professionals and scientists for their work in fighting ...
(Date:6/24/2016)... (PRWEB) , ... June 24, 2016 , ... ... now offering micro-osteoperforation for accelerated orthodontic treatment. Dr. Cheng has extensive experience with ... Damon brackets , AcceleDent, and accelerated osteogenic orthodontics. , Micro-osteoperforation is a ...
(Date:6/24/2016)... NY (PRWEB) , ... June 24, 2016 , ... Topical BioMedics, Inc, makers of Topricin ... companies that call for a minimum wage raise to $12 an hour by 2020 and ... This will restore the lost value of the minimum wage, assure the wage floor does ...
(Date:6/24/2016)... ... June 24, 2016 , ... EB Medicine presented its ... Emergency Medicine conference in Ponte Vedra Beach, FL. The awards honor the outstanding ... Medicine Practice and Pediatric Emergency Medicine Practice. , “With this award, we ...
(Date:6/24/2016)... ... June 24, 2016 , ... Puradigm® & Innovative Solutions today ... cultivation and processing operations at its production facility, and opened its first two ... the manufacturer of a complete system of proactive air and surface purification solutions ...
Breaking Medicine News(10 mins):
(Date:6/24/2016)... June 24, 2016 Research ... "Structural Electronics 2015-2025: Applications, Technologies, Forecasts" ... In-Mold Electronics, Smart Skin, Structural Health ... Structural electronics involves electronic and/or electrical ... structures, replacing dumb structures such as vehicle bodies ...
(Date:6/24/2016)... Mass. and SAN CLEMENTE, Calif. , ... California -based mobile pulmonary function testing company, is now able ... PFT devices developed by ndd Medical Technologies , Inc. ... testing done in hospital-based labs.  Thanks to ndd,s EasyOne PRO ® ... , can get any needed testing done in the comfort ...
(Date:6/24/2016)...   Pulmatrix, Inc ., (NASDAQ: PULM ... announced today that it was added to the Russell ... comprehensive set of U.S. and global equity indexes on ... milestone for Pulmatrix," said Chief Executive Officer Robert ... progress in developing drugs for crucial unmet medical needs, ...
Breaking Medicine Technology: